Known targets — ChEMBL curated mechanism
CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CHRM1CHRM2CHRM3CHRM4CHRM5
The experimentally established mechanism targets of Terodiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 1.00 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 1.00 |
| ▸ | CACNA1C known ✓ | Q13936 | 2/20 | 1.00 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 1.00 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 1.00 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 1.00 |
| ▸ | CACNA1S known ✓ | Q13698 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 5/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terodiline SCHEMBL9008621 | 1.00 | HRH1 (1.00) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| Terodiline SCHEMBL121864 | 0.98 | HRH1 (0.96) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| Terodiline SCHEMBL579993 | 0.98 | HRH1 (0.96) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| Terodiline SCHEMBL110026 | 0.96 | HRH1 (0.93) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| Terodiline SCHEMBL8149719 | 0.94 | HRH1 (0.89) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| SCHEMBL9008867 | 0.90 | ADRA1A (0.81) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| SCHEMBL9008606 | 0.90 | ADRA1A (0.81) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| SCHEMBL9107533 | 0.90 | ADRA1A (0.81) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| SCHEMBL9108716 | 0.90 | ADRA1A (0.81) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| SCHEMBL9008774 | 0.90 | ADRA1A (0.81) | HRH1ADRA1ASLC6A3KCNH2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5275 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558405-B2 | Pharmaceutical composition using endogenous cells for preventing or treating musculoskeletal disorders | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2026-02-24 | — | — | US | claimed |
| WO-2025029873-A9 | TREATMENT OF HAIR-LOSS DISORDER | Q32 BIO INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-3872055-B1 | SOLVENT-FREE CROSS-COUPLING REACTION, AND PRODUCTION METHOD USING SAID REACTION | UNIV HOKKAIDO NAT UNIV CORP (JP) | 2025-04-09 | — | — | EP | claimed |
| WO-2025029873-A2 | TREATMENT OF HAIR-LOSS DISORDER | Q32 BIO INC. (US) | 2025-02-06 | — | — | WO | claimed |
| WO-2025029859-A2 | TREATMENT OF ATOPIC DERMATITIS | Q32 BIO INC. (US) | 2025-02-06 | — | — | WO | claimed |
| US-20240299348-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. | 2024-09-12 | — | — | US | claimed |
| US-12004868-B2 | Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel | SIGNPATH PHARMA INC. (US) | 2024-06-11 | — | — | US | claimed |
| EP-4335005-A1 | COUNTER PUMPING A LARGE MODE AREA FIBER LASER | Optical Engines, Inc. (US) | 2024-03-13 | — | — | EP | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| US-20230201148-A1 | USES OF ORNITHINE PHENYLACETATE FOR TREATING HYPERAMMONEMIA | MALLINCKRODT LLC | 2023-06-29 | — | — | US | claimed |
| US-5629008-A | Method and device for long-term delivery of drugs | C.R. BARD, INC. (US) | 1997-05-13 | — | — | US | claimed |
| WO-1996027375-A2 | USE OF DEXTROMETHORPHAN OR DEXTRORPHAN FOR THE TREATMENT OF URINARY INCONTINENCE | ALGOS PHARMACEUTICAL CORPORATION (US) | 1996-09-12 | — | — | WO | claimed |
| US-5492933-A | SIDE EFFECT REDUCTION | SEPRACOR, INC. (US) | 1996-02-20 | — | — | US | claimed |
| WO-1995033511-A1 | METHOD AND DEVICE FOR LONG-TERM DELIVERY OF DRUGS | C.R. BARD, INC. (US) | 1995-12-14 | — | — | WO | claimed |
| WO-1995010269-A1 | TREATMENT OF URINARY INCONTINENCE AND OTHER DISORDERS WITH R-TERODILINE AND HYDROXYLATED DERIVATIVES THEREOF | SEPRACOR, INC. (US) | 1995-04-20 | — | — | WO | claimed |
| WO-1995010270-A1 | METHOD FOR TREATING URINARY INCONTINENCE USING OPTICALLY PURE S-TERODILINE | SEPRACOR, INC. (US) | 1995-04-20 | — | — | WO | claimed |
| EP-0572932-A2 | Method and implant device for long term delivery of drugs | C.R. BARD, INC. (US) | 1993-12-08 | — | — | EP | claimed |
| WO-1991007366-A1 | A PROCESS FOR PREPARING R(+)-TERODILINE AND SALTS THEREOF | KABI PHARMACIA AKTIEBOLAG (SE) | 1991-05-30 | — | — | WO | claimed |
| EP-0427904-A1 | A process for preparing R(+)-terodiline and salts thereof | KabiVitrum AB (SE) | 1991-05-22 | — | — | EP | claimed |
| US-4851404-A | USING CALCIUM PLOCKERS | MILES INC. (US) | 1989-07-25 | — | — | US | claimed |